Controlled Cell Killing by a Recombinant Nonsegmented Negative-Strand RNA Virus  by Parks, Griffith D. et al.
Virology 293, 192–203 (2002)Controlled Cell Killing by a Recombinant Nonsegmented Negative-Strand RNA Virus
Griffith D. Parks,*,1 Virginia A. Young,* Constantinos Koumenis,† Elizabeth K. Wansley,*
Jennifer L. Layer,* and Kelly M. Cooke
*Department of Microbiology and Immunology and †Radiation Oncology and Cancer Biology, Wake Forest University School of Medicine,
Winston-Salem, North Carolina 27157-1064
Received September 26, 2001; returned to author for revision November 6, 2001; accepted November 12, 2001
In most tissue culture cell lines tested, infection with the paramyxovirus simian virus 5 (SV5) results in very little cell death.
To determine if SV5 could be used as a vector for controlled killing of tumor cells, a recombinant SV5 (rSV5-TK) was
constructed to encode the herpes simplex virus thymidine kinase (TK) gene. MDBK cells infected with rSV5-TK showed a
time-dependent loss of viability when infected cells were cultured in the presence of the prodrug acyclovir (ACV) or
ganciclovir (GCV) while no significant toxicity was observed in the absence of prodrug. Cells infected with a control rSV5
expressing GFP and cultured with prodrug showed only a slight reduction in growth rate and little cell death. Time-lapse video
microscopy of rSV5-TK-infected MDBK cells that were cultured in the presence of ACV showed an accumulation of cells with
morphological effects characteristic of apoptotic cell death. An MDBK cell line persistently infected with rSV5-TK retained
long-term expression of TK and sensitivity to prodrug-mediated cell killing that were comparable to those found in an acute
infection. Titration experiments showed that the rSV5-TK plus GCV combination resulted in cell death for all mouse and
human cell lines tested, although the kinetics and efficiency of cell death varied between cell types. Our results demon-INTRODUCTION
There has been remarkable progress in recent years
on the development of reverse genetics systems for
manipulating negative-strand RNA viruses. As such, a
number of nonsegmented negative-strand RNA viruses
have been engineered to express a variety of foreign
proteins (reviewed in Conzelmann, 1998; Pekosz et al.,
1999; Palese, 1995). The ability to recover paramyxo- and
rhabdoviruses from cDNA has raised the possibility of
using these viruses as therapeutic vectors for the deliv-
ery of genes or toxins for cancer therapy. In this report,
we have engineered a noncytopathic negative-strand
RNA virus to express an enzyme that activates a prodrug
and demonstrated that this vector can be used for con-
trolled cell killing.
The paramyxovirus simian virus 5 (SV5) is a member of
the rubulaviruses, a group that includes mumps virus,
human parainfluenza virus type 2, and SV41 (Lamb and
Kolakofsky, 1996). The 15-kb negative-sense RNA ge-
nome encodes seven tandemly linked genes (Fig. 1A)
that code for the nucleocapsid protein (NP), which binds
the viral RNA genome; the phospho- (P) and large (L)
proteins, which together constitute the viral polymerase;
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192the matrix protein involved in virus assembly; and the
membrane proteins HN and F, which are responsible for
cell attachment and fusion, respectively. The V and small
hydrophobic (SH) proteins are thought to be involved in
counteracting cellular innate immune responses to SV5
infection. The V protein is important for blocking inter-
feron signaling in SV5-infected cells by targeting the
degradation of cellular STAT1 protein (Didcock et al.,
1999). The SH protein serves an unknown function in the
viral life cycle, but infection of cells with a recombinant
SV5 (rSV5) lacking the SH gene results in the induction of
apoptosis (He et al., 2001).
SV5 has inherent properties that could be exploited to
generate novel therapeutic vectors. One such property is
that infection with SV5 results in very little cell death in
most tissue cell lines tested (e.g., Choppin, 1964; He et
al., 2001). We reasoned that a paramyxovirus that does
not induce a dramatic cytopathic effect could serve as a
vector for controlled killing of infected cells. We hypoth-
esize that an rSV5 vector could be engineered to express
a well-characterized enzyme that would induce cell
death in a controlled manner and by a mechanism which
is understood.
The herpes simplex virus (HSV) thymidine kinase (TK)
protein in conjunction with acyclovir (ACV) or ganciclovir
(GCV) is a prototype system for controlled cell killing and
has been used extensively as a “suicide gene” in astrating controlled cell killing by a recombinant paramyxovir
vectors for targeted killing of cancer cells. © 2002 Elsevier S
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phosphorylates the nontoxic prodrugs ACV and GCV,
converting them into potent intracellular compounds that
can be incorporated into host DNA and ultimately induce
cell death (Elion et al., 1977). Thus, cell killing is con-
trolled with the TK/GCV combination, since it occurs in
cells that express TK and are exposed to the prodrug. In
addition, the “bystander effect” that results from the TK/
GCV combination allows neighboring cells within a tu-
mor microenvironment to also become susceptible to
GCV-mediated killing (Mesnil and Yamasaki, 2000). To
test our hypothesis on the use of rSV5 as a vector for
controlled cell killing, we have engineered a recombi-
nant SV5 (rSV5-TK) to express the HSV TK gene. We
show that infection of a variety of cell lines with rSV5-TK
results in very little virus-mediated cell death, but exten-
sive cell killing can be induced when rSV5-TK-infected
cells are exposed to ACV or GCV. Our results support the
use of negative-strand RNA viruses as therapeutic vec-
tors for controlled killing of cancer cells.
RESULTS
Recovery of rSV5 expressing the HSV TK protein
Previous work has indicated that extensions to the
carboxy-terminus of TK do not affect enzyme activity
(Loimas et al., 1998). Thus, to facilitate detection of the TK
gene product, the 3 end of the TK open reading frame
was extended to include an 11-amino-acid epitope rec-
ognized by an anti-HA monoclonal antibody. The result-
ing TK-HA gene was modified by a PCR to be flanked by
gene start and gene end signals from the SV5 NP–P/V
and HN–L junctions, respectively, and then inserted at
the HN–L junction encoded in the SV5 infectious cDNA
clone (Fig. 1A). Virus was recovered from cells trans-
fected with the resulting plasmid as described previously
(He et al., 1997) and was designated rSV5-TK.
Western blotting with anti-HA antibody was carried out
to determine a time course of TK expression in cells
infected with rSV5-TK. As shown in Fig. 1B, MDBK cells
infected with rSV5-TK synthesized an 45-kDa polypep-
tide (TK-HA) by 8 h postinfection (p.i.) that was not de-
tected in mock infected cells (lane M). A faster migrating
form of TK was also detected at lower levels that may
represent a degradation product. The kinetics of TK de-
tection in cells infected with rSV5-TK was slightly de-
layed relative to NP and P, consistent with the gradient of
viral transcription and the position of the TK gene in a 3
promoter-distal site in the SV5 genome.
For some negative-strand RNA viruses, the insertion of
a foreign gene can influence viral growth characteristics
(e.g., Sakai et al., 1999; Skiadopoulos et al., 2000). To
determine if inserting the TK gene into the SV5 genome
affected the rate of virus growth, a single-step growth
analysis was carried out on cells infected at a high m.o.i.
with rSV5 WT, rSV5-TK, or a control virus containing the
GFP gene at the HN–L junction (rSV5-GFP; He et al.,
1997). As shown in Fig. 1C, the insertion of the TK gene
into rSV5 did not affect virus growth, since each of the
rSV5 viruses showed very similar growth rates in MDBK
cells and reached 109 PFU/ml as a final titer.
ACV-mediated killing of MDBK cells infected
with rSV5-TK
Cells infected with rSV5-TK were treated with varying
concentrations of ACV to determine if they were sensi-
tized to killing by the prodrug. Monolayers of MDBK cells
were mock infected or infected with rSV5-TK or the con-
trol virus rSV5-GFP at an m.o.i. of 50 and then cultured
in the presence of ACV (0–20 g/ml). After 48 h, cells
were removed from the dishes and the number of viable
cells was determined by counting cells that excluded
trypan blue staining. As shown in Fig. 2A, the number of
viable cells remaining after 48 h is expressed as a fold
change relative to the number of cells in the culture
before infection. In the absence of ACV, the number of
viable MDBK cells increased six- to eightfold after infec-
tion with either rSV5-GFP or rSV5-TK (0 bars, Fig. 2A).
This result is consistent with previous reports that SV5
infection is largely noncytopathic in MDBK cells (e.g., He
et al., 2001). With the addition of ACV to the culture
media, the number of mock- or rSV5-GFP-infected cells
increased by approximately three- to fivefold. By con-
trast, adding as little as 1 g/ml ACV to the growth media
of cells infected with rSV5-TK prevented an increase in
the number of viable cells over the 2-day assay period
(black bars, Fig. 2A). At ACV concentrations higher than
1 g/ml, the number of viable cells decreased from the
original number of cells at the time of infection by two- to
fourfold.
Figure 2B shows a time course of the change in the
number of viable MDBK cells after mock infection or
infection with rSV5-GFP or rSV5-TK. In the absence of
ACV, the number of viable cells by 48 h p.i. increased
approximately fourfold regardless of whether they were
mock infected or infected with rSV5-GFP or rSV5-TK
(dashed lines, Fig. 2B). For mock-infected or rSV5-GFP-
infected cells, these increases in numbers of viable cells
were not significantly affected by including ACV in the
media (filled triangles and squares, Fig. 2B). However, in
the presence of 20 g/ml ACV, rSV5-TK-infected cell
numbers were essentially unchanged after the first day
p.i., and viable cell numbers decreased two- to threefold
by 48 h p.i. (filled circles).
The changes in cell number shown in Fig. 2 reflect the
proliferation, survival, and death of cells in the popula-
tion. Time-lapse video microscopy was carried out to
more closely monitor cytopathic changes to individual
rSV5-TK-infected MDBK cells after exposure to ACV. Fig-
ure 3 shows pictures from a representative experiment in
which MDBK cells were infected with rSV5-TK (Figs.
3A–3C) or rSV5-GFP (Figs. 3D–3F) and cultured in the
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presence of 10 g/ml ACV. By 24 h p.i. with rSV5-TK,
there was an accumulation of cells that had rounded up
without undergoing cell division (Fig. 3B). By 48 h p.i.,
there was a significant decrease in the number of cells in
the field, with many of the dying cells having character-
istics of apoptotic cells including cell rounding, mem-
brane blebbing, and an accumulation of cellular debris.
In the case of rSV5-GFP-infected cells cultured with ACV,
there were fewer rounded cells than in the rSV5/ACV
cultures, and the majority of these rounded cells subse-
quently underwent cell division. To quantitate the cyto-
pathic effect of rSV5-TK, the number of rounded cells that
FIG. 1. Genome structure, protein expression, and growth of rSV5-TK. (A) Structure of rSV5-TK. The SV5 genome is depicted as a rectangle with
vertical bars denoting the intergenic regions. The 3 leader (le) and 5 trailer (tr) are shown as dark boxes. The HSV TK open reading frame was
modified to encode a 3-end HA epitope tag and was flanked on the 3 and 5 sides by the gene end–intergenic–gene start signals from the NP–PV
and the HN–L gene junctions, respectively. (B) TK expression from rSV5-TK. MDBK cells were mock infected (M lane) or infected with rSV5-TK. At the
indicated hours p.i., cells were lysed and equal aliquots analyzed by Western blotting with polyclonal antisera specific for the SV5 NP and P proteins
(top) or an HA-specific monoclonal antibody (bottom). (C) Growth of rSV5-TK. MDBK cells were infected at an m.o.i. of 20 with rSV5 WT, rSV5-GFP,
or rSV5-TK and medium was harvested at the indicated times p.i. Virus titers were determined by plaque assay on CV-1 monolayers. Data represent
the averages of two experiments.
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did not undergo cell division was calculated as a mea-
sure of a defined cytopathic effect. The graph at the
bottom of Fig. 3 shows the results from a representative
experiment in which the accumulation of rounded cells is
expressed as a percentage of the total number of cells in
the field. When cultured with ACV, the rSV5-TK-infected
cell population showed an initial lag in accumulation of
rounded cells up to 18–24 h p.i. (filled squares), con-
sistent with the time course of cell viability shown in Fig.
1B above. However, by 48 h p.i., nearly 70% of the cells in
the field had rounded up and many had disintegrated
into cellular debris. By contrast, for rSV5-TK-infected cells
without ACV (filled triangles) or for rSV5-GFP-infected
cells exposed to ACV (open squares) only 2 and 5%,
respectively, of the infected cells in these control sam-
ples had rounded up without undergoing cell division by
48 h p.i. Taken together, these data demonstrate con-
trolled cell killing of MDBK cells by a negative-strand
RNA virus vector, since only the combination of rSV5-TK
infection and ACV treatment induces a significant loss of
MDBK cell viability.
Susceptibility of various cell lines to GCV-mediated
killing by rSV5-TK
A variety of cell lines were tested for their sensitivity to
cell killing by rSV5-TK along with GCV, a prodrug that we
have found to have a lower nonspecific effect on mock-
FIG. 2. Controlled killing of MDBK cells infected with rSV5-TK in the presence of ACV. (A) Titration of ACV effect. Monolayers of MDBK cells were
mock infected or infected with rSV5-TK or rSV5-GFP. Growth media were supplemented with ACV to the indicated concentrations. Two days later,
viable cell numbers were determined by trypan exclusion and are expressed as the fold change from the initial number of infected cells. Data are
the means ( standard deviation, SD) of three independent experiments. (B) Time course of ACV effect. MDBK cell monolayers were mock infected
or infected with rSV5-TK or rSV5-GFP. The growth media were supplemented with either 0 (dashed lines) or 20 g/ml ACV (solid lines). At 1 and 2
days p.i., viable cell numbers were determined as described for A. Data are the means of three independent experiments. For clarity, the SDs are
shown only for rSV5-TK plus ACV, but all other SD were within 20%.
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infected cells (not shown). Figure 4 shows representative
results of a GCV titration of six cell lines infected with
rSV5-TK: bovine kidney MDBK cells, murine breast can-
cer 4T1 cells, human monocytic-like U937 cells, human
HeLa cells, and human lung A549 and H1299 cells. Cells
were mock infected or infected with rSV5-TK or the con-
trol virus rSV5-GFP at high m.o.i. After 48 h in the pres-
ence of various concentrations of GCV (0–200 M), the
fold change in viable cell numbers was determined com-
pared to the starting culture.
Several features of rSV5-TK cell killing are evident in
the results shown in Fig. 4. First, infection of some cell
lines with either rSV5-GFP or rSV5-TK in the absence of
added GCV resulted in a lower fold increase in cell
number compared to mock infected cells (Fig. 4, 0 GCV
bars). This reduction in growth of infected cells is most
evident in the case of HeLa and A549 cells and is
consistent with the report that SV5 infection slows pro-
gression through the HeLa cell cycle (Lin and Lamb,
2000). Second, culturing uninfected cells (Fig. 4, white
bars) or rSV5-GFP-infected control cells (hatched bars)
with the highest GCV concentration (200 M) resulted in
a slight decrease in cell growth compared to no added
GCV, with the magnitude of this effect being dependent
on the particular cell type assayed. Most importantly, the
combination of infection with rSV5-TK and GCV treatment
showed a significant reduction of viable cell numbers in
each cell line tested. The efficiency of cell killing with
FIG. 3. Time-lapse video microscopy of MDBK cells infected with rSV5-TK or rSV5-GFP in the presence of ACV. Flasks of MDBK cells were infected
with rSV5-TK (top row, A–C) or rSV5-GFP (bottom row, D–F) and incubated in medium containing 10 g/ml ACV. Time-lapse video microscopy of a field
of infected cells was carried out as described under Materials and Methods. Selected video frames are shown representing time 0 (A and D), 24 h
p.i. (B and E), and 48 h p.i. (C and F). In the bottom graph, the number of rounded cells that did not undergo cell division was determined as an assay
of cytopathic effects at the indicated times p.i. The accumulation of rounded cells is expressed as a percentage of the total number of cells in the
field. Data are representative of two independent experiments.
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rSV5-TK and GCV varied between cell lines as evident by
comparing the results with MDBK and 4T1 cells. MDBK
cells were very sensitive to GCV-induced cell killing by
rSV5-TK, and a significant loss of viability was seen with
as little as 2 M GCV. For the rSV5-TK-infected 4T1
murine breast cancer cell line, there was a lower overall
loss of viability with increasing doses of GCV compared
to MDBK cells and significant decreases in cell numbers
from the starting culture were seen only at the higher
GCV concentrations. The individual cell lines also
showed a difference in the kinetics of cell killing. For
example, the profile of rSV5-TK cell killing for human lung
A549 cells was similar to that of U937 cells; however, the
significant loss of viability shown in Fig. 4 for A549 cells
was delayed until 4 days p.i. as opposed to the 2 days
needed for killing of the other cell lines.
The sensitivity of various cell lines to rSV5-TK-medi-
ated cell killing was not strictly related to cell growth
FIG. 4. Sensitivity of various cell lines to GCV-mediated killing by rSV5-TK. MDBK, 4T1, U937, HeLa, A549, or H1299 cells were infected with rSV5-TK
(black bars) or rSV5-GFP (hatched bars), or mock infected (white bars), and the media were supplemented with the indicated concentrations of GCV.
After 2 days, viable cell numbers were determined by trypan blue exclusion and are expressed as the fold change from the initial number of infected
cells. For A549 cells, viable cell numbers were determined at 4 days p.i. Data are representative of at least two independent experiments. The
doubling time (DT) of each cell line was determined as described under Materials and Methods.
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rate. As shown in Fig. 4, MDBK cells had the shortest
doubling time (11.5 h) and were the most sensitive to
GCV-mediated killing by rSV5-TK. However, 4T1 cells had
a similar doubling time (DT12 h) and were significantly
less sensitive to rSV5-TK/GCV-mediated killing. U937 and
A549 cells had similar doubling times (20 and 17.5 h,
respectively), but A549 cells took 4 days to show a
significant loss of viability. Likewise, Western blot anal-
ysis showed that the efficiency of rSV5-TK cell killing was
not strictly linked to the level of SV5 or TK proteins
expressed (not shown). Taken together, the most impor-
tant conclusion from these data is that every cell line
tested shows controlled cell killing by the rSV5-TK and
GCV combination.
Effect of p53 levels on the efficiency of rSV5-TK
cell killing
More than 50% of human cancers have been found to
contain mutations in the tumor suppressor protein p53
(Greenblatt et al., 1994). Thus, preferential replication or
killing of cells that are defective in p53 would be a
desirable characteristic of a therapeutic viral vector. The
H1299-derived human lung cancer cell line HT7, which
contains a doxycycline-inducible p53 gene (Koumenis et
al., 2001), was used to determine if rSV5-TK gene expres-
sion or growth was altered by different levels of p53. HT7
cells were mock treated or treated for 20 h with 0.5 g/ml
doxycycline to induce synthesis of p53 before infection
with rSV5-TK. As shown in Fig. 5A, p53 levels were
increased by doxycycline treatment ( lanes) relative to
control untreated samples ( lanes) and these levels
were maintained in rSV5-infected cells at 24 h p.i. West-
ern blotting of cell extracts prepared 24 h p.i. showed no
significant difference in the accumulation of viral P and
TK proteins (Fig. 5A, 24 h lanes). Likewise, the final yields
of rSV5-TK from HT7 cells did not differ significantly
between cultures that were induced to synthesize p53
and control uninduced cells (data not shown).
There are conflicting reports on whether p53 plays an
important role in cell killing by the TK plus GCV combi-
nation (Krohne et al., 2001; Matsubara et al., 1999; Wal-
lace et al., 1996). To determine the influence of p53 on
the efficiency of rSV5-TK cell killing, doxycycline-treated
or mock-treated HT7 cells were infected with rSV5-TK
and cultured with various concentrations of GCV (0–200
M). After 3 days, viable cell numbers were determined.
In the absence of rSV5-TK infection, doxycycline treat-
ment resulted in a slight decrease in cell numbers rela-
tive to control untreated cells (Fig. 5B, no virus bars),
consistent with the induced p53 having a negative effect
on cell growth. HT7 cells infected with rSV5-TK showed a
dose-dependent loss of viability with increasing concen-
trations of GCV from 2 to 200 M. At each GCV concen-
tration, there were fewer cells remaining in cultures that
were treated with doxycycline versus untreated control
FIG. 5. Effect of increased levels of p53 protein on the growth and
efficiency of cell killing by rSV5-TK. (A) Increased levels of p53 do not
alter the level of protein expression from rSV5-TK. HT7 cells were mock
treated ( lanes) or treated with 0.5 g/ml doxycycline ( lanes) for
20 h prior to mock infection or infection with rSV5-TK. Cell lysates were
prepared immediately after infection (0 lanes) or 24 h p.i. in the pres-
ence or absence of 0.5 g/ml doxycycline. Equivalent amounts of
protein from each sample were assayed by Western blotting with
antibodies specific for p53, P, or TK-HA. (B) Effect of increased levels of
p53 on cell killing by rSV5-TK. HT7 cells were mock treated or treated
with 0.5 g/ml doxycycline (Dox) for 20 h prior to infection with rSV5-TK.
Cells were then cultured with or without doxycycline and the indicated
concentrations of GCV. After 3 days, viable cell numbers were deter-
mined as described under Materials and Methods. (C) Induction of p53
sensitizes HT7 cells to GCV. HT7 cells were treated for 18 h with 0.5
g/ml doxycycline or 200 M GCV for 2 days and numbers of viable
cells were determined. Data represent the means of three independent
experiments (standard deviation) and are expressed as the fold
change in the number of viable cells relative to the starting culture.
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cultures. However, this loss of viability was not solely
due to killing by rSV5-TK infection. This is evident in Fig.
5C, where doxycycline-treated cells were also more sen-
sitive to GCV, even in the absence of virus infection. This
can be attributed to a combined effect of p53-dependent
inhibition of cell growth and an increased basal toxicity
of GCV in the presence of p53. Together, these data
suggest that p53 is not required for rSV5-TK/GCV cell
killing but may increase the efficiency of prodrug action
in human cells.
GCV-mediated killing of MDBK cells persistently
infected with rSV5-TK
The above results indicate that cells acutely infected
with rSV5-TK are susceptible to GCV-mediated killing. We
established an MDBK cell line persistently infected (PI)
with rSV5-TK to determine if these cells retained their
sensitivity to GCV-mediated killing. Immunofluorescence
microscopy with anti-P antibodies demonstrated the
presence of SV5 antigen in 95% of the PI cells that had
been maintained for over 15 cell passages (not shown).
The PI cells showed no obvious difference in growth
characteristics or morphology relative to uninfected cells
or cells acutely infected with rSV5-TK. To determine the
relative expression levels of viral and TK protein, cell
lysates were prepared from mock-infected MDBK cells,
the PI cell line, or MDBK cells at 48 h p.i. with rSV5-TK.
Serial dilutions of lysates were analyzed by immunoblot-
ting using a dot-blot format and antibodies for the SV5
NP and TK proteins. As shown in Fig. 6A, cells acutely
infected with rSV5-TK (S lanes) accumulated slightly
more NP and TK protein at 48 h p.i. than was found for
the PI cell line (P). As shown in Fig. 6B, exposure of the
PI cell line to 2 M GCV resulted in a significant de-
crease in cell numbers relative to mock-infected cells,
with larger decreases seen at higher GCV concentra-
tions. The efficiency of GCV-mediated cell killing was
slightly higher than that seen for cells infected with
rSV5-TK for 2 days. Thus, the PI cell line appears to be
more sensitive to GCV-mediated cell killing than the cells
acutely infected with rSV5-TK.
DISCUSSION
In this report we have tested the hypothesis that a
nonsegmented negative-strand RNA virus could be en-
gineered as a vector for controlled killing of infected
cells. Our rationale was that the inherently noncytopathic
virus SV5 could express a foreign protein to kill cells in a
controlled manner and by mechanisms that are relatively
well understood. In most tissue culture cell lines tested,
rSV5 infection results in very little cell death (e.g., Chop-
pin, 1964; He et al., 2001). Using time-lapse video micros-
copy, we have found that by 48 h p.i. less than 5% of a
population of MDBK cells infected with rSV5-TK have
rounded up without undergoing cell division, a common
cytopathic effect of viral infections. This result is consis-
tent with the results of He et al. (2001), who showed by
TUNEL assay that there was no significant difference
between mock-infected and rSV5-infected MDBK cells in
the fraction of cells displaying markers of apoptosis.
While SV5 infection of some cell types, such as CV-1 and
BHK, leads to extensive cell–cell fusion (e.g., Horvath
FIG. 6. Cells persistently infected with rSV5-TK retain sensitivity to GCV-mediated killing. (A) Expression of viral and TK proteins in acute and
persistently infected MDBK cells. Lysates were prepared from rSV5-TK persistently infected MDBK cells (P lanes), from MDBK cells infected for 48 h
with rSV5-TK (S lanes) or from mock-infected control cells (M lanes). After protein concentrations were normalized (starting with 0.2 and 2 g of protein
for NP and TK samples, respectively), serial dilutions of lysate were analyzed by dot-blot hybridization using antiserum specific for the SV5 NP protein
or the HA-tagged TK protein. (B) Effect of GCV on the viability of MDBK cells persistently infected with rSV5-TK. The growth media on monolayers of
mock-infected, rSV5-TK-infected, and the pass 15 MDBK PI cell line were supplemented with GCV to the indicated concentrations. After 2 days, viable
cell numbers were determined as described in the legend to Fig. 2.
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and Lamb, 1992), this is not the most common outcome
of an SV5 infection and none of the cell lines tested here
showed overt SV5-induced syncytia. Paterson et al.
(1989) have created SV5 F protein cleavage site mutants
with reduced potential to cause cell–cell fusion. It should
be possible to further reduce the potential for cytopathic
effects from SV5 infection but still retain infectivity by
incorporating these F protein mutants into the rSV5-TK
vector.
Our assays for changes in cell viability following in-
fection have shown that SV5 infection has a minor effect
on cell growth. When assayed over a 2-day period in the
absence of prodrug, rSV5-TK and rSV5-GFP infection of
some cell types resulted in a two- to threefold decrease
in cell number compared to mock-infected cells (see Fig.
4). This observation is consistent with a previous de-
tailed analysis showing that SV5-infected HeLa cells
proliferated more slowly than mock-infected cells. Lin
and Lamb (2000) have reported that SV5-infected HeLa
cells display both a small delay at the beginning of S
phase and an extended length of the S phase of cellular
growth. The SV5 V protein is responsible for altering the
HeLa cell cycle during infection (Lin and Lamb, 2000),
and this may be due to the interaction of V protein with
the cellular damage-specific DNA binding protein (Lin et
al., 1998). For the purposes of using rSV5-TK in targeted
cell killing, a delay in entering S phase could be an
advantage, since it is possible that the infected cell
would build up higher levels of phosphorylated GCV for
incorporation into host DNA.
Each cell type tested in this study lost viability using
the rSV5-TK plus GCV combination, although the effi-
ciency and kinetics of cell killing were not always the
same. This was evident by our finding that the most
efficient cell killing occurred with MDBK cells, while
murine 4T1 cells showed the least efficient killing. Hu-
man A549 lung cells were unique among the cell lines
tested, since significant cell killing of rSV5-TK-infected
cells was not evident until 4 days p.i., which was later
than the 2 days required for all other cell types. A number
of factors can contribute to the sensitivity of a cell line to
GCV/TK-mediated killing, including cell growth rate, level
of TK expression (Chen et al., 1999; Kim et al., 2000) and
activity (Drake et al., 1999), uptake of GCV, and the status
of cellular apoptotic pathways. In the cell lines tested
here, we found no direct correlation between the effi-
ciency with which a cell line was killed by rSV5-TK and
either the cell growth rate or the expression level for TK
and SV5 proteins. Work is in progress to determine the
efficiency of cell killing and cytopathic properties of our
rSV5-TK vector in primary cells.
The mechanism of cell killing by the combination of TK
plus ACV/GCV is thought to be by apoptosis (Hamel et
al., 1996; Wallace et al., 1996), although nonapoptotic
pathways for TK/GCV killing have been reported for
some cells (e.g., Halloran and Fenton, 1998). Since a
number of viruses have been shown to encode compo-
nents that act to block apoptotic pathways in infected
cells (Griffin and Hardwick, 1997; Roulston et al., 1999,
and references therein), we initially anticipated that SV5
might have a mechanism(s) that could inhibit apoptosis
induced by the TK plus ACV/GCV combination. Recent
data suggest that the SV5 SH protein may be involved in
counteracting apoptosis during an SV5 infection (He et
al., 2001). Our results indicate that any SV5-mediated
block in an apoptotic pathway can be overcome by the
combination of TK expression plus prodrug treatment.
However, an effective therapeutic vector based on
rSV5-TK will need to be more efficient and potent at cell
killing. It remains to be determined if expression of the
TK gene from the rSV5-SH virus previously described
by He et al. (2001) will enhance the rate or the overall
extent of cell killing by rSV5-TK. Alternatively, it may be
possible to enhance cell killing further by engineering
rSV5 to express well-defined inducers of apoptosis (e.g.,
Bax).
The finding that p53 suppressor protein is nonfunc-
tional in greater than 50% of human tumors (Greenblatt et
al., 1994) suggests that it may be possible to design viral
vectors that could selectively replicate in and kill p53-
deficient cells but not p53-wt cells. Despite initial indi-
cations that this held true for a therapeutic E1B 55-kDa-
deleted mutant adenovirus, recent data have shown that
the growth properties of this vector do not always corre-
late with the status of p53 (Dix et al., 2001; Goodrum and
Ornelles, 1998). Our results with a human lung cell line
containing an inducible p53 gene indicate that protein
expression and growth of rSV5-TK are not affected by
large differences in expression of p53. While cells in-
duced for overexpression of p53 in our experimental
system were sensitized to GCV-mediated death in the
absence of rSV5-TK infection, we conclude that p53 sta-
tus is unlikely to be a major factor influencing the ability
of our current rSV5-TK vector to kill tumor cells.
There are a number of advantages to using paramyxo-
viruses as therapeutic vectors, including the apparent
lack of strict packaging constraints, cytoplasmic replica-
tion without DNA integration, and the ability to incorpo-
rate foreign glycoproteins into the virion envelope. A
potential disadvantage of their use as safe therapeutic
vectors is their capacity to establish persistent infections
both in cell culture and in vivo (reviewed by Randall and
Russell, 1991). We have shown that an MDBK cell line
persistently infected with rSV5-TK retained long-term ex-
pression of TK and sensitivity to GCV-mediated cell kill-
ing similar to those found in an acute infection. This
result supports the proposal that including the TK gene
in recombinant negative-strand viruses could improve
the safety of these vectors by providing a means to
control or eliminate a persistent viral infection. In addi-
tion, these data indicate that the noncytopathic nature of
rSV5 infection provides a means to obtain long-term
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expression of foreign genes without overt changes in the
infected cells.
Controlled cell killing and selective cell targeting are
two critical features for a virus to be useful in targeted
therapy of cancer cells (reviewed in Verma and Somia,
1997; Anderson, 1998). The results reported here with
rSV5-TK provide proof-of-concept addressing the first
requirement, in which an inherently noncytopathic virus
has been engineered to kill cells by a mechanism that
can be controlled. SV5 has inherent properties that can
be also exploited to address the second requirement of
selective cell targeting. The SV5 F protein is capable of
promoting membrane fusion without the SV5 HN attach-
ment protein (e.g., Horvath and Lamb, 1992; Lamb, 1993).
This raises the possibility that the SV5 HN protein with a
binding specificity for sialic acid could be replaced with
an attachment protein with specificity for a targeted cel-
lular receptor. The approach of redirecting a viral infec-
tion has recently been demonstrated for measles virus,
another negative-strand RNA virus. Selective cell target-
ing has been achieved by using recombinant measles
viruses that contain chimeric attachment proteins con-
sisting of the viral H protein linked to epidermal growth
factor or to a single chain antibody (Hammond et al.,
2001; Schneider et al., 2000). Work is in progress to
engineer rSV5 to encode both the TK gene for controlled
cell killing and a chimeric attachment protein for target-
ing of the viral infection to selected cell types.
MATERIALS AND METHODS
Cells, viruses, and plaque assays
Cultures of cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) or RPMI 1640 containing 10%
fetal calf serum (FCS). The 4T1 murine breast cancer cell
line was kindly provided by Fred Miller (University of
Michigan). The p53-inducible H7 human lung cells have
been described (Koumenis et al., 2001). All other cell
lines were obtained from the Comprehensive Cancer
Center of Wake Forest University. To determine doubling
times, 105 cells were plated in 3.5-cm dishes and at
various times, cells were removed from the dish and
counted using a Coulter counter. Vaccinia virus MVA
expressing T7 RNA polymerase was a kind gift from B.
Moss and was grown and titered on BHK cells (Wyatt et
al., 1995). Single-step growth kinetics and plaque assays
were carried out as described previously (Parks et al.,
2001). An m.o.i. of 50 was used for all infections with rSV5
vectors. An MDBK cell line persistently infected with
rSV5-TK was established by infecting 106 cells at an
m.o.i. of 50 and passing the resulting cells every 4–5
days.
Recovery of rSV5 expressing TK
The full-length SV5 infectious cDNA clone pBH276 (He
et al., 1997) was kindly provided by B. He and R. A. Lamb
(Northwestern University). A SphI–SalI DNA fragment en-
coding the HN–L junction was modified by a PCR using
Pwo polymerase (Boehringer Mannheim) and subcloned
into pGem3 to generate pG3-HNL-MCS, such that the
HN–L junction contained a multiple cloning site with
EcoRV and SalI restriction enzyme sequences. A plasmid
(pPEP78) encoding the herpes simplex TK gene was
kindly provided by Dr. Peter Pertel (Northwestern Univer-
sity). The TK gene was modified by a PCR to remove the
internal SphI site and add a 3-terminal Asp718 site
without changing the encoded amino acids. The result-
ing PCR product was inserted into pG3-HA such that the
translation open reading frame was fused at the 3 end
to a 10-amino-acid segment recognized by an anti-HA
antibody (YPYDVPDYA). The TK-HA gene was inserted
into pG3-HNL-MCS such that the gene was flanked on
the 3 and 5 sides by transcription signals from the
NP–P and HN–L junctions, respectively (Fig. 1A; Rassa
and Parks, 1999), and the overall length was a multiple of
6 (Murphy and Parks, 1997). A SphI–SalI DNA fragment
encoding the TK-HA gene was excised and then inserted
into the corresponding sites in the SV5 full-length cDNA
clone (He et al., 1997) to yield pRSV5-TK. SV5 virus
expressing the HA-tagged TK protein was recovered
from pRSV5-TK as described previously (He et al., 1997)
with minor modifications (Parks et al., 2001). Virus stocks
were generated from a single plaque by growth in MDBK
cells. Wild-type (WT) rSV5 and rSV5-GFP were similarly
isolated from pBH276 and pBH311, respectively (He et al.,
1997).
Western blotting
MDBK cells plated in 24-well dishes were infected
with rSV5 WT, rSV5-GFP. or rSV5-TK at an m.o.i. of 20
for 1 h. Cells were washed and covered with DMEM/2%
FCS. At each time point, cells were washed with PBS and
lysed in gel loading buffer and equal aliquots of cell
lysate were analyzed on a 10% polyacrylamide gel. Pro-
teins were transferred to nitrocellulose using a semidry
electrophoretic transfer cell (15 V, 15 min). Nitrocellulose
membranes were blocked (5% milk in PBS) and probed
using a rat monoclonal antibody specific for an HA
epitope (anti-HA clone 3F10; Roche Molecular Biochemi-
cals) or rabbit antisera to the SV5 NP and P proteins
(Parks et al., 2001). For measuring p53 levels, HT7 cells
(Koumenis et al., 2001) were treated for 20 h with 0.5
g/ml doxycycline in RPMI/2% FBS to induce synthesis
of p53, and cell lysates were analyzed by Western blot-
ting with mouse monoclonal DO-1 specific for human
p53 (Santa Cruz Biotechnology). Proteins were visualized
using HRP-conjugated goat secondary antibodies and
ECL (Pierce Chemicals). For dot-blot analysis, the protein
concentration of infected cell lysates was determined
using the BCA assay (Pierce Chemicals). Equivalent
amounts of protein were serially diluted in PBS and
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applied to nitrocellulose using a vacuum manifold before
analysis by Western blotting with antibodies specific for
TK, NP, or P proteins.
Cell killing assays and time-lapse video microscopy
Between 1 and 5  105 cells in six-well dishes were
mock infected or infected at an m.o.i. of 50 with rSV5-GFP
or rSV5-TK for 1 h. Cells were covered in media contain-
ing 2% FCS and various concentrations of ACV or GCV
(Sigma Chemicals) as described in the figure legends. At
the indicated times postinfection, cells were washed and
trypsinized (for adherent cells), and viable cell numbers
were determined by trypan blue exclusion. Data are
expressed as a fold increase in cell number relative to
the starting culture.
Time-lapse video microscopy was carried out using
25-cm2 flasks of MDBK cells that were mock infected or
infected with rSV5-GFP or rSV5-TK. Cells were cultured in
the presence of 10 g/ml ACV on a time-lapse micros-
copy system (37°C, 5% CO2) using a Zeiss inverted Ax-
iovert phase-contrast microscope with an attached video
camera. Pictures were recorded at intervals on standard
VHS tape. Digital images for Fig. 3 were derived from the
VHS tape. The accumulation of rounded cells that did not
undergo cell division was determined as a function of
time and is expressed as a percentage of the total
number of cells in the field.
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